B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. Patent applications |
Patent application number | Title | Published |
20140257146 | LOW INTENSITY ULTRASOUND THERAPY - Methods of treating a subject suffering from a disease or a disorder associated with hyperproliferating cells. The method includes non-invasively administering to the subject ultrasound at a low intensity in a dose effective to selectively prevent the growth of the hyperproliferating cells or to eliminate the hyperproliferating cells in the subject, while substantially not affecting the cell viability of normal cells of the subject. The low intensity is pre-determined to be lower than a cavitational threshold intensity for a selected frequency. | 09-11-2014 |
20140247043 | HIGH RESOLUTION PLANAR HALL EFFECT SENSORS - The present invention discloses a planar Hall-effect sensor with a magnetic sensing region of an elongated shape, wherein, for a ratio of long axis length to short axis length greater than a predetermined number, effective single magnetic domain behavior is exhibited in the sensing region, the sensing having shape-induced uniaxial magnetic anisotropy with the easy axis parallel to the long axis of the magnetic sensing region; further wherein the magnitude of the uniaxial magnetic anisotropy depends on the ratio of the thickness of the sensing region to the length of the short axis. | 09-04-2014 |
20140120126 | COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 05-01-2014 |
20110319790 | PHARMACEUTICAL COMPOSITION AND SYSTEM FOR PERMEABILIZING FETAL MEMBRANES - Provided is a pharmaceutical composition for permeabilizing fetal membranes including an active ingredient having a log K in the range of 2 to 4, where K is the octanol/water partition coefficient. The active ingredient may be, for example, bupivacaine, sodium lauryl sulfate or oleic acid. Further provided is a system for transfetal membrane transport. The system includes a probe unit adapted for insertion into a female reproductive tract and releasing a substance onto fetal membranes that permeabilizes the membranes. The system is also configured to apply ultrasound radiation to the fetal membranes to further increase the membrane permeability. | 12-29-2011 |
20110256165 | COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 10-20-2011 |
20080279878 | Compositions of Hsp60 Peptides and Viral Antigens for Vaccination and Diagnosis - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 11-13-2008 |